Analgesic
Suzetrigine
search
Suzetrigine
, Journavx
See Also
Analgesic
Indications
Moderate to severe acute pain in adults
Contraindications
Severe hepatic
Impairment
(
Child-Pugh Class
C)
Reduce dose in moderate hepatic
Impairment
Mechanism
Non-
Opioid Analgesic
with unique mechanism, released in 2024 at $15/pill
Sodium Channel Blocker
developed for use in acute pain
Blocks transmission of
Peripheral Nerve
pain sesnsation
Dosing
First Dose: 100 mg orally on an empty
Stomach
(except clear liquids)
May be taken with clear liquids (water, apple juice, tea or black coffee)
First dose should be taken >1 hour before or >2 hours after food
Subsequent Doses: 50 mg orally every 12 hours
May be taken with or without food
May be used for up to 14 days (longer courses have not been studied)
Adverse Effects
Pruritus
Rash
Myalgias
May be associated with increased
Creatine Phosphokinase
(CPK)
Safety
Avoid in pregnancy (unknown safety)
Avoid in
Lactation
(present in animal milk, unknown safety)
Drug Interactions
CYP3A Inhibitor
s
Avoid with use of strong
CYP3A Inhibitor
s (e.g.
Itraconazole
)
Avoid
Grapefruit
juice while on Suzetrigine
CYP3A Inducer
s
Avoid with moderate to strong
CYP3A Inducer
s (e.g.
Rifampin
)
Progestin
s (other than
Levonorgestrel
or
Norethindrone
)
If used for
Contraception
, use an alternate contracepive while taking Suzetrigine and for 28 days after
Efficacy
Initial studies were with <1000 middle aged white women post-op (e.g.
Bunion
surgery, Abdominoplasty)
Limited broader efficacy data
Very expensive ($15/dose in 2025) for a medication with efficacy likely similar to
Vicodin
Resources
Suzetrigine (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0976da4-1d20-4517-945c-b60ed2f41c12
References
(2025) Presc Insights, Issue 3/2025
Type your search phrase here